Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update.

The updated results corroborated the previously reported favourable cost-effectiveness ratio of CAR-T. They also pointed out differences among CAR-T agents. However, their budget impact emerges as a significant barrier in the reimbursement process. Any proposed Managed Entry Agreement must integrate the ingrained uncertainty of long-term efficacy and precede reimbursement decisions.